{
    "clinical_study": {
        "@rank": "55169", 
        "arm_group": [
            {
                "arm_group_label": "Docetaxel", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Docetaxel plus Suramin", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The overall purpose of the study is to determine whether or not the inclusion of suramin to\n      standard treatment with docetaxel improves progression-free survival for patients with\n      advanced non-small cell lung cancer in the second and third line settings."
        }, 
        "brief_title": "Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Carcinoma, Non Small Cell Lung", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "The overall purpose of the study is to determine whether or not the inclusion of suramin to\n      standard treatment with docetaxel improves progression-free survival for patients with\n      advanced non-small cell lung cancer in the second and third line settings.\n\n      Secondary objectives include:\n\n        -  To compare response rate of patients in both treatment arms\n\n        -  To compare overall survival of patients in both treatment arms\n\n        -  To compare toxicity in both treatment arms\n\n        -  To determine whether the survival benefit from suramin is associated with reduced\n           M-phase entry in peripheral blood lymphocytes"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Pathologically proven diagnosis of non-small cell lung cancer\n\n          -  Documented disease progression after first-line chemotherapy for non-small cell lung\n             cancer\n\n          -  Stable and treated CNS metastasis is allowed\n\n          -  Radiation must be completed at least 2 weeks prior to starting protocol treatment\n\n          -  Major surgery must be completed at least 4 weeks prior to starting protocol treatment\n\n          -  ECOG performance status 0-2\n\n          -  Sexually active patients must use adequate contraception\n\n          -  Adequate bone marrow function\n\n          -  Adequate renal function\n\n          -  Adequate liver function\n\n        Exclusion Criteria:\n\n          -  Severe hypersensitivity reaction to docetaxel\n\n          -  Pre-existing grade 3 or 4 neuropathy\n\n          -  Women who are pregnant or breastfeeding\n\n          -  Uncontrolled intercurrent illness\n\n          -  Receipt of 3 or more prior chemotherapy regimens"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 25, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01671332", 
            "org_study_id": "CO11508"
        }, 
        "intervention": [
            {
                "arm_group_label": "Docetaxel", 
                "description": "IV over 60 minutes, 75 mg/m2", 
                "intervention_name": "Docetaxel", 
                "intervention_type": "Drug", 
                "other_name": "Taxotere"
            }, 
            {
                "arm_group_label": "Docetaxel plus Suramin", 
                "description": "IV over 30 minutes", 
                "intervention_name": "Suramin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Docetaxel plus Suramin", 
                "description": "IV over 60 minutes. 56 mg/m2", 
                "intervention_name": "Docetaxel", 
                "intervention_type": "Drug", 
                "other_name": "Taxotere"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Suramin", 
                "Docetaxel"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Carcinoma, non small cell lung", 
            "Second line", 
            "Third line"
        ], 
        "lastchanged_date": "April 17, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Madison", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53792"
                    }, 
                    "name": "University of Wisconsin Carbone Comprehensive Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milwaukee", 
                        "country": "United States", 
                        "state": "Wisconsin"
                    }, 
                    "name": "Medical College of Wisconsin"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized Phase II Study of Suramin and Docetaxel Versus Docetaxel in Non-Small Cell Lung Cancer After Failure of First-Line Chemotherapy", 
        "overall_official": [
            {
                "affiliation": "University of Wisconsin, Madison", 
                "last_name": "Anne M Traynor, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Medical College of Wisconsin", 
                "last_name": "Rafael Santana-Davila, MD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression-free survival in months", 
            "safety_issue": "No", 
            "time_frame": "From the time of randomization to the time of progression of disease, evaluated every 6 weeks, for up to 52 weeks."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01671332"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Response rate per RECIST 1.1 criteria", 
                "safety_issue": "No", 
                "time_frame": "From baseline to the time of response, evaluated every 6 weeks, for up to 52 weeks."
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "From the time of registration to the time of death, assessed once each month for up to 50 months"
            }, 
            {
                "description": "The investigators will compare the toxicity profiles of the two arms of therapy to determine if the docetaxel + suramin has a more favorable toxicity profile than docetaxel alone.", 
                "measure": "Toxicity/Adverse Events from treatment", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 of each cycle of treatment, and 30 days post end of treatment"
            }, 
            {
                "description": "The investigators hypothesize that suramin in combination with docetaxel improves response rates and survival by preventing the cancer cells to enter M phase of the cell cycle.", 
                "measure": "Evaluation of peripheral blood lymphocytes for DNA damage-induced checkpoint control.", 
                "safety_issue": "No", 
                "time_frame": "Baseline"
            }
        ], 
        "source": "University of Wisconsin, Madison", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Medical College of Wisconsin", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Optimum Therapeutics, LLC", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Ohio State University", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "University of Wisconsin, Madison", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}